Breakthrough in COVID-19 Prevention: Inhaled Vaccine Shows Promise in Clinical Trial

Revolutionizing COVID-19 Vaccination with Inhaled Aerosol Vaccines?

Inhaled Aerosol COVID-19 Vaccine Shows Robust Mucosal Immunity in Phase 1 Trial

A phase 1 clinical trial of a next-generation inhaled aerosol COVID-19 vaccine has demonstrated promising safety and immunogenicity results, potentially addressing a critical gap in current vaccination strategies. The McMaster University-led study found that a single dose of a chimpanzee adenoviral-vectored (ChAd) multi-antigenic vaccine effectively induced robust respiratory mucosal immunity in participants previously vaccinated with mRNA vaccines, regardless of prior SARS-CoV-2 infection status.

The trial, published in Nature Communications, evaluated escalating doses of both human adenovirus serotype 5 (HuAd) and chimpanzee adenovirus serotype 68 (ChAd) vaccines delivered via inhaled aerosol. The vaccines contained a triple-antigen design targeting the S1 portion of the spike protein, nucleocapsid, and RNA-dependent RNA polymerase – a significant departure from first-generation vaccines focused solely on the spike protein. Importantly, the ChAd-vectored vaccine demonstrated superior immunogenicity compared to its HuAd counterpart.

"Our findings reveal a minimal presence of mucosal immunity within the lower respiratory tract of intramuscular mRNA-vaccinated humans, even after prior SARS-CoV-2 infection," said the study authors. "This highlights a significant immunological gap in current vaccine strategies that our approach may effectively address." The researchers noted that while mRNA vaccines generate strong systemic antibody responses, they fail to induce robust mucosal immunity in the lungs – the primary site of SARS-CoV-2 infection.

How Were the Vaccine Trials Designed and Conducted?

The study enrolled 36 healthy adults who had received at least two doses of an approved mRNA COVID-19 vaccine. Twenty-seven participants without prior SARS-CoV-2 infection were assigned to receive escalating doses (10^5 to 3 × 10^7 TCID50) of either HuAd or ChAd vaccines, with an additional group receiving the highest dose (10^8 TCID50) of the ChAd vaccine. Nine participants with previous SARS-CoV-2 infection received either 3 × 10^7 or 6 × 10^7 TCID50 of the ChAd vaccine. The vaccines were delivered using the Aeroneb® Solo Vibrating Mesh Nebulizer, which generates aerosols between 2-5 micrometers in diameter, ideal for deposition in the major airways.

Both vaccine candidates were well-tolerated across all tested doses, with only mild and short-duration adverse events reported. The most common side effects included fatigue, headache, and cough, with no severe adverse reactions documented. Importantly, there were no changes in respiratory function following vaccination, as measured by spirometry through 12 weeks post-vaccination.

What Immune Responses Did the Vaccine Elicit?

The most striking finding was the vaccine's ability to induce what researchers termed "tripartite mucosal immunity" – consisting of tissue-resident memory CD8 T cells, neutralizing antibodies, and trained innate immunity in alveolar macrophages. This comprehensive immune response was particularly robust at the optimal 6 × 10^7 TCID50 dose of the ChAd vaccine. The vaccine-induced T cells demonstrated cross-reactivity against divergent SARS-CoV-2 variants, including Omicron XBB.1.5, suggesting potential broad protection despite viral evolution.

Comprehensive immunological analysis revealed that the majority of vaccine-specific CD8 T cells in the airways displayed a tissue-resident memory phenotype, expressing surface markers CD103 and CD69 involved in cell adhesion and tissue retention. Nearly 75% of CD8 T cells specific to vaccine-encoded antigens induced by the high-dose ChAd vaccine displayed this tissue-resident memory phenotype, compared to only 40-50% induced by the lower dose. Additionally, all CD8 T cells specific to vaccine-encoded antigens expressed VLA-4 (α4β1), which contributes to T cell homing to the lung and plays a role in tissue retention.

How Does the Vaccine Shape Innate Immunity?

Transcriptomic analysis of alveolar macrophages before and after vaccination revealed significant changes in gene expression profiles associated with trained innate immunity. Genes involved in IL-1 signaling, cholesterol biosynthesis, and NOD2 signaling were upregulated in alveolar macrophages after vaccination, consistent with the development of trained innate immunity. This was further supported by functional analysis showing heightened responsiveness to secondary stimulation, with significantly increased production of TNF and IL-8.

What Do Systemic Immune Responses Indicate?

The study also revealed that inhaled aerosol vaccination induced significant systemic immune responses in the blood, with increased vaccine-specific T cells exhibiting lung-homing capabilities. These circulating T cells strongly correlated with mucosal responses, suggesting they could serve as biomarkers for successful induction of respiratory immunity following vaccination. The vaccine-induced memory T cells persisted for up to 48 weeks in peripheral blood.

How Does the Inhaled Vaccine Compare to Existing Options?

This approach contrasts with other COVID-19 vaccines in development for respiratory mucosal delivery, most of which target only the spike protein. The only other authorized inhaled aerosol COVID-19 vaccine, Ad5-nCoV, showed limited effectiveness compared to its intramuscular counterpart in a recent study – a limitation potentially explained by the current findings demonstrating the inferior respiratory mucosal immunogenicity of Ad5-vectored vaccines.

What Are the Future Implications of This Trial?

The results have significant implications for future vaccine development strategies against respiratory pathogens. "Our findings not only support further clinical development of this COVID vaccine strategy but also provide the proof of concept for developing inhaled aerosol vaccines against other respiratory pathogens," the researchers concluded.

The trial is registered with ClinicalTrials.gov (NCT05094609), and the researchers are planning expanded clinical studies to further evaluate the vaccine's efficacy and long-term protection against SARS-CoV-2 variants.

Industry Context: As SARS-CoV-2 continues to evolve, generating variants that evade neutralizing antibodies induced by current vaccines, the pharmaceutical industry is increasingly focused on next-generation strategies that can provide more comprehensive protection. This trial demonstrates that respiratory mucosal vaccination may offer a promising alternative to conventional intramuscular approaches, particularly for respiratory pathogens. The ability to induce robust and durable mucosal immunity with a single inhaled dose could significantly impact future vaccine development pipelines, with implications extending beyond COVID-19 to other respiratory infections like influenza and RSV.

Summary

A Phase 1 clinical trial led by McMaster University has successfully tested an inhaled aerosol COVID-19 vaccine that demonstrates superior immunogenicity and safety. The study evaluated both human and chimpanzee adenovirus-vectored vaccines containing three antigens, with the chimpanzee variant showing better results. The trial included 36 adults previously vaccinated with mRNA vaccines, testing various doses delivered via nebulizer. The vaccine induced comprehensive "tripartite mucosal immunity," including tissue-resident memory CD8 T cells, neutralizing antibodies, and trained innate immunity in alveolar macrophages. Notably, the vaccine-induced T cells showed cross-reactivity against various SARS-CoV-2 variants, including Omicron XBB.1.5. The results suggest potential applications beyond COVID-19 for other respiratory pathogens, marking a significant advancement in vaccine development strategies.